Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
Marc Peeters
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Kelly S. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Timothy Jay Price
Consultant or Advisory Role - Amgen (U)
Honoraria - Amgen
Andres Cervantes
No relevant relationships to disclose
Alberto F. Sobrero
Consultant or Advisory Role - Amgen; Bayer; Merck; Roche; Sanofi
Honoraria - Amgen; Bayer; Celgene; Roche; Sanofi
Michel Ducreux
Consultant or Advisory Role - Roche
Honoraria - Amgen; Bayer; Biocompatibles; Merck; Pfizer; Roche
Research Funding - Pfizer; Roche
Yevhen Hotko
Disclosure not yet available
Thierry Andre
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Emily Chan
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Florian Lordick
Consultant or Advisory Role - Amgen; GANYMED Pharmaceuticals
Research Funding - Fresenius Biotech; GlaxoSmithKline
Cornelis J. A. Punt
No relevant relationships to disclose
Andrew Strickland
No relevant relationships to disclose
Gregory Wilson
Honoraria - Amgen
Other Remuneration - Amgen
Tudor-Eliade Ciuleanu
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Laslo Roman
No relevant relationships to disclose
Eric Van Cutsem
Research Funding - Amgen
Ying Tian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Andre Scott Jung
Employment or Leadership Position - Amgen
Roger Sidhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Scott D. Patterson
Employment or Leadership Position - Amgen
Stock Ownership - Amgen